{"id":"clopidogrel-prasugrel-ticagrelor","safety":{"commonSideEffects":[{"rate":"2-5","effect":"Bleeding (major and minor)"},{"rate":"1-3","effect":"Dyspnea"},{"rate":"1-2","effect":"Bradycardia"},{"rate":"1-2","effect":"Rash"},{"rate":"1-2","effect":"Gastrointestinal bleeding"}]},"_chembl":{"chemblId":"CHEMBL1201772","moleculeType":"Small molecule","molecularWeight":"373.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clopidogrel, prasugrel, and ticagrelor are antiplatelet agents that block the P2Y12 receptor on platelets, preventing ADP-induced platelet activation and aggregation. They are used to reduce the risk of stent thrombosis and recurrent cardiovascular events in patients undergoing percutaneous coronary intervention or with acute coronary syndromes. These drugs are often used in dual antiplatelet therapy (DAPT) alongside aspirin.","oneSentence":"These are P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:18.608Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (NSTEMI, STEMI)"},{"name":"Prevention of stent thrombosis following percutaneous coronary intervention"},{"name":"Secondary prevention of cardiovascular events in patients with prior myocardial infarction or stroke"}]},"trialDetails":[{"nctId":"NCT05681702","phase":"PHASE4","title":"Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI","status":"RECRUITING","sponsor":"University of Florida","startDate":"2023-02-15","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT06588595","phase":"PHASE4","title":"The Switching Antiplatelet-9 (SWAP-9) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-11-01","conditions":"Coronary Arterial Disease (CAD)","enrollment":90},{"nctId":"NCT05531474","phase":"NA","title":"Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2020-11-02","conditions":"Cardiovascular Complication, Bariatric Surgery Candidate","enrollment":200},{"nctId":"NCT04471870","phase":"","title":"ARCANGELO (itAlian pRospective Study on CANGrELOr)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2020-10-23","conditions":"Acute Coronary Syndrome","enrollment":1005},{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT04654052","phase":"PHASE4","title":"VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación EPIC","startDate":"2021-07-02","conditions":"Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease","enrollment":634},{"nctId":"NCT06535568","phase":"NA","title":"Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","status":"RECRUITING","sponsor":"Fondazione Ricerca e Innovazione Cardiovascolare ETS","startDate":"2026-01-10","conditions":"Coronary Disease, Heart Diseases, Cardiovascular Diseases","enrollment":576},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT07164859","phase":"PHASE3","title":"Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI","status":"NOT_YET_RECRUITING","sponsor":"Vincent ROULE","startDate":"2025-10","conditions":"Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI), Antiplatelet Therapy","enrollment":1700},{"nctId":"NCT06665919","phase":"NA","title":"The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models","status":"COMPLETED","sponsor":"Vistamedi Ltd.","startDate":"2023-06-15","conditions":"Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis","enrollment":283},{"nctId":"NCT06710262","phase":"","title":"T-TAS® wS Method Comparison","status":"COMPLETED","sponsor":"Hikari Dx, Inc.","startDate":"2024-08-21","conditions":"Antiplatelet Therapy, Healthy Donors, Von Willebrand Disease (VWD)","enrollment":115},{"nctId":"NCT03430661","phase":"PHASE1","title":"A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2018-01-24","conditions":"Healthy","enrollment":77},{"nctId":"NCT06763744","phase":"PHASE4","title":"Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-06-01","conditions":"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk","enrollment":3000},{"nctId":"NCT05952206","phase":"PHASE3","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","status":"RECRUITING","sponsor":"iVascular S.L.U.","startDate":"2023-10-13","conditions":"Coronary Artery Disease","enrollment":2312},{"nctId":"NCT04505774","phase":"PHASE4","title":"Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE","status":"COMPLETED","sponsor":"Matthew Neal MD","startDate":"2020-09-04","conditions":"Covid19","enrollment":3591},{"nctId":"NCT03606642","phase":"PHASE2","title":"SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy","status":"TERMINATED","sponsor":"HonorHealth Research Institute","startDate":"2018-11-19","conditions":"Coronary Artery Disease, Atherosclerosis, Stent Placement","enrollment":50},{"nctId":"NCT05955365","phase":"PHASE4","title":"Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-12-18","conditions":"Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF), Oral Anticoagulation","enrollment":3010},{"nctId":"NCT06613191","phase":"PHASE4","title":"Colonoscopy and Antiplatelet Therapy Trial","status":"NOT_YET_RECRUITING","sponsor":"Ochsner Health System","startDate":"2024-10-01","conditions":"Coronary Arterial Disease (CAD), Peripheral Vascular Disease","enrollment":100},{"nctId":"NCT05418556","phase":"PHASE4","title":"Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-10-21","conditions":"Coronary Artery Disease","enrollment":3944},{"nctId":"NCT05117866","phase":"NA","title":"Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Meditrix Corp","startDate":"2020-09-15","conditions":"Chronic Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":307},{"nctId":"NCT02886962","phase":"PHASE4","title":"Oral Anticoagulation in Haemodialysis Patients","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2017-07-12","conditions":"Kidney Failure, Chronic","enrollment":50},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06484647","phase":"","title":"Comparing T-stenting And Minimal Protrusion With External Minicrush for Treatment of Complex Coronary Bifurcation","status":"RECRUITING","sponsor":"San Luigi Gonzaga Hospital","startDate":"2024-06-01","conditions":"Coronary Artery Disease, Ischemic Heart Disease, Chronic Coronary Syndrome","enrollment":382},{"nctId":"NCT03419325","phase":"EARLY_PHASE1","title":"A Genomic Approach for Clopidogrel in Caribbean Hispanics","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Puerto Rico","startDate":"2020-09-01","conditions":"Cardiovascular Disease (CVD), Stroke, Acute Coronary Syndrome","enrollment":150},{"nctId":"NCT02317198","phase":"PHASE4","title":"Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2013-06","conditions":"Non-ST-elevation Acute Coronary Syndrome, Unstable Angina, Non-ST-elevation Myocardial Infarction","enrollment":1011},{"nctId":"NCT06400940","phase":"PHASE4","title":"Prospective, Post-registration, Interventional, Randomized, in Parallel Groups, Multicenter Eurasian Clinical Study of DERIVO®/DERIVO® Mini Aneurysm Embolization Device, Europe-Asia","status":"RECRUITING","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2023-08-17","conditions":"Intracranial Aneurysm","enrollment":640},{"nctId":"NCT01556659","phase":"NA","title":"LV Thrombus After Acute AMI: A Randomized Controlled Trial","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2012-03","conditions":"Ventricular Thrombosis Mural Following Myocardial Infarction","enrollment":25},{"nctId":"NCT05262803","phase":"PHASE4","title":"Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction","status":"RECRUITING","sponsor":"Rikke Sorensen","startDate":"2022-06-17","conditions":"Myocardial Infarction","enrollment":2808},{"nctId":"NCT05223335","phase":"PHASE4","title":"Clopidogrel Monotherapy in Patients With High Bleeding Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-03-29","conditions":"Bleeding Complications","enrollment":98},{"nctId":"NCT05773989","phase":"PHASE4","title":"Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy","status":"UNKNOWN","sponsor":"St. Antonius Hospital","startDate":"2024-01-23","conditions":"Coronary Artery Disease, Platelet Reactivity","enrollment":88},{"nctId":"NCT05903976","phase":"PHASE3","title":"De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Policlinico \"G. Martino\"","startDate":"2023-06-12","conditions":"Dual Antiplatelet Therapy, Acute Coronary Syndrome, Coronary Artery Disease","enrollment":200},{"nctId":"NCT04981041","phase":"PHASE4","title":"Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2021-12-16","conditions":"Acute Coronary Syndrome, Atrial Fibrillation","enrollment":2334},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT05821062","phase":"","title":"Antiplatelet Therapies in Patients With Depression and Coronary Disease","status":"UNKNOWN","sponsor":"Centro Cardiologico Monzino","startDate":"2022-04-14","conditions":"Coronary Artery Disease, Depression","enrollment":400},{"nctId":"NCT05122741","phase":"","title":"Modulation of Fibrosis-inducing Pathways in Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"University of Messina","startDate":"2021-12-01","conditions":"Myocardial Infarction, Myocardial Fibrosis, Myocardial Remodeling, Ventricular","enrollment":50},{"nctId":"NCT02601157","phase":"PHASE4","title":"Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-01-18","conditions":"Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction","enrollment":2173},{"nctId":"NCT05599152","phase":"","title":"Comparison of Myocardial Infarction Patients Who Were Prescribed a Novel Antiplatelet Agent or Clopidogrel","status":"UNKNOWN","sponsor":"Chan Joon Kim","startDate":"2020-05-21","conditions":"Myocardial Infarction","enrollment":3000},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT02271022","phase":"","title":"Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-02-17","conditions":"Acute Coronary Syndromes","enrollment":2000},{"nctId":"NCT02605447","phase":"PHASE4","title":"EVOLVE Short DAPT Study","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2016-02-16","conditions":"Coronary Artery Disease","enrollment":2009},{"nctId":"NCT03489863","phase":"PHASE4","title":"Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-05-30","conditions":"Coronary Artery Disease","enrollment":14},{"nctId":"NCT02944123","phase":"PHASE3","title":"Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2016-09","conditions":"Acute Coronary Syndrome","enrollment":120},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":"Covid19","enrollment":1707},{"nctId":"NCT02264912","phase":"","title":"The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2008-07","conditions":"Platelet Aggregation Onhibitors","enrollment":2016},{"nctId":"NCT02866175","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2017-02-24","conditions":"Atrial Fibrillation","enrollment":1506},{"nctId":"NCT02247128","phase":"PHASE4","title":"Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2014-01","conditions":"Aortic Valve Disease, Myocardial Infarction, Stroke","enrollment":1016},{"nctId":"NCT04291287","phase":"","title":"Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)","status":"UNKNOWN","sponsor":"Scientific Institute San Raffaele","startDate":"2020-01-25","conditions":"Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding","enrollment":1500},{"nctId":"NCT02635230","phase":"","title":"What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.","status":"UNKNOWN","sponsor":"R&D Cardiologie","startDate":"2014-06","conditions":"Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes","enrollment":2200},{"nctId":"NCT03621020","phase":"","title":"Clinical Performance Evaluation of T-TAS 01 PL Chip","status":"COMPLETED","sponsor":"Hikari Dx, Inc.","startDate":"2018-09-01","conditions":"Platelet Dysfunction, Von Willebrand Diseases, Healthy","enrollment":307},{"nctId":"NCT02376283","phase":"PHASE4","title":"P3AMI Antiplatelet Trial","status":"COMPLETED","sponsor":"The Royal Wolverhampton Hospitals NHS Trust","startDate":"2015-03-09","conditions":"Heart Attack","enrollment":87},{"nctId":"NCT02581280","phase":"","title":"Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2014-12","conditions":"Cardiac Dysfunction","enrollment":56},{"nctId":"NCT02285751","phase":"PHASE2","title":"High \"on Treatment\" Platelet Reactivity in the Intensive Care Unit","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2012-11","conditions":"Critical Illness","enrollment":200},{"nctId":"NCT02302508","phase":"PHASE4","title":"Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients","status":"WITHDRAWN","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2019-09-01","conditions":"Diabetes","enrollment":""},{"nctId":"NCT02030548","phase":"","title":"Bleeding in Patients Undergoing CABG (Coronary Artery Bypass Graft) During Dual Antiplatelet Therapy","status":"TERMINATED","sponsor":"Medical University of Graz","startDate":"2013-11","conditions":"Acute Coronary Syndrome","enrollment":144},{"nctId":"NCT01761786","phase":"PHASE4","title":"Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)","status":"COMPLETED","sponsor":"Vera HM Deneer","startDate":"2011-06","conditions":"Myocardial Infarction, STEMI","enrollment":2700},{"nctId":"NCT03111420","phase":"NA","title":"Study of AggreGuide A-100 (ADP) Assay","status":"COMPLETED","sponsor":"Aggredyne, Inc.","startDate":"2017-01-09","conditions":"Risk Factor, Cardiovascular, Platelet Dysfunction Due to Drugs","enrollment":280},{"nctId":"NCT02118870","phase":"PHASE4","title":"Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent","status":"COMPLETED","sponsor":"Diagram B.V.","startDate":"2014-06-10","conditions":"Acute Coronary Syndrome","enrollment":1500},{"nctId":"NCT03823547","phase":"","title":"Future Optimal Research and Care Evaluation","status":"RECRUITING","sponsor":"J.M. ten Berg","startDate":"2015-01-01","conditions":"Acute Coronary Syndrome, Myocardial Infarction","enrollment":99999},{"nctId":"NCT02044146","phase":"PHASE2, PHASE3","title":"A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2014-09","conditions":"Acute Coronary Syndrome, Percutaneous Coronary Intervention","enrollment":120},{"nctId":"NCT01589978","phase":"PHASE4","title":"PROMUS Element Plus US Post-Approval Study","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2012-05","conditions":"Coronary Artery Disease","enrollment":2681},{"nctId":"NCT03184805","phase":"NA","title":"STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation","status":"TERMINATED","sponsor":"Yonsei University","startDate":"2017-06-23","conditions":"Coronary Artery Disease","enrollment":140},{"nctId":"NCT01701453","phase":"NA","title":"Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2012-08","conditions":"Acute Coronary Syndrome","enrollment":2712},{"nctId":"NCT02293395","phase":"PHASE2","title":"A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-04-20","conditions":"Acute Coronary Syndrome","enrollment":3037},{"nctId":"NCT03347435","phase":"NA","title":"Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes","status":"TERMINATED","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2013-06","conditions":"Acute Coronary Syndromes","enrollment":889},{"nctId":"NCT01967615","phase":"","title":"P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2015-01","conditions":"Coronary Arteriosclerosis","enrollment":4500},{"nctId":"NCT01830543","phase":"PHASE3","title":"A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-05-10","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2124},{"nctId":"NCT02215993","phase":"PHASE4","title":"Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2013-07","conditions":"Acute Coronary Syndrome, Platelet Function","enrollment":50},{"nctId":"NCT01515345","phase":"PHASE3","title":"Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry","status":"COMPLETED","sponsor":"Kaiser Franz Josef Hospital","startDate":"2011-07","conditions":"Platelet Inhibition, Coronary Stent Implantation","enrollment":1008},{"nctId":"NCT03103685","phase":"PHASE4","title":"Continue vs. Stop P2Y12 Inhibitor on Bleeding in Patient Receiving DAPT Undergoing Dental Procedure.","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2017-05-01","conditions":"Dental Diseases, Antiplatelet Agents, Antiplatelet Drugs","enrollment":428},{"nctId":"NCT02587260","phase":"PHASE4","title":"Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2015-12-17","conditions":"Cardiovascular Diseases","enrollment":54},{"nctId":"NCT01700322","phase":"PHASE4","title":"Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study","status":"COMPLETED","sponsor":"Johannes Gutenberg University Mainz","startDate":"2012-08","conditions":"Coronary Artery Disease","enrollment":126},{"nctId":"NCT01276275","phase":"","title":"Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-01","conditions":"Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout","enrollment":7200},{"nctId":"NCT01823185","phase":"PHASE4","title":"Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy","status":"UNKNOWN","sponsor":"Imam Abdulrahman Bin Faisal University","startDate":"2013-03","conditions":"Coronary Artery Disease, Myocardial Infarction, Heart Disease","enrollment":1500},{"nctId":"NCT02190123","phase":"","title":"REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09","conditions":"Treatment of Acute Coronary Syndrome (ACS).","enrollment":430},{"nctId":"NCT02026713","phase":"PHASE4","title":"Potential Impact of Cigarette Smoking on Platelet Reactivity in Patients on Dual Antiplatelet Therapy With P2Y12 Inhibitors","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2014-07","conditions":"Coronary Artery Disease","enrollment":150},{"nctId":"NCT02402491","phase":"PHASE4","title":"Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2013-01","conditions":"Percutaneous Coronary Intervention","enrollment":1000},{"nctId":"NCT02108808","phase":"PHASE4","title":"Effect of Ticagrelor on Fractional Flow Reserve","status":"COMPLETED","sponsor":"University of Patras","startDate":"2014-04","conditions":"Fractional Flow Reserve","enrollment":76},{"nctId":"NCT02303717","phase":"NA","title":"Xience Versus Synergy in Left Main PCI","status":"UNKNOWN","sponsor":"NHS National Waiting Times Centre Board","startDate":"2014-12","conditions":"Coronary Artery Disease","enrollment":818},{"nctId":"NCT01477775","phase":"PHASE4","title":"Customized Choice of Oral P2Y12 Receptor Blocker","status":"UNKNOWN","sponsor":"Italian Society of Invasive Cardiology","startDate":"2012-01","conditions":"Acute Coronary Syndrome, Coronary Angioplasty","enrollment":4000},{"nctId":"NCT01543932","phase":"PHASE3","title":"High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2012-07","conditions":"Coronary Artery Disease","enrollment":81},{"nctId":"NCT01456364","phase":"PHASE4","title":"Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing","status":"UNKNOWN","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2011-09","conditions":"Coronary Heart Disease","enrollment":70},{"nctId":"NCT01385319","phase":"PHASE3","title":"Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study","status":"UNKNOWN","sponsor":"Marco Valgimigli","startDate":"2011-06","conditions":"Coronary Artery Disease","enrollment":1606},{"nctId":"NCT01360437","phase":"PHASE3","title":"Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"University of Patras","startDate":"2011-05","conditions":"Coronary Artery Disease, Acute Coronary Syndrome","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Plavix","Brilinta","Effient"],"phase":"marketed","status":"active","brandName":"Clopidogrel, Prasugrel, Ticagrelor","genericName":"Clopidogrel, Prasugrel, Ticagrelor","companyName":"Centre hospitalier de l'Université de Montréal (CHUM)","companyId":"centre-hospitalier-de-l-universit-de-montr-al-chum","modality":"Small molecule","firstApprovalDate":"","aiSummary":"These are P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events. Used for Acute coronary syndrome (NSTEMI, STEMI), Prevention of stent thrombosis following percutaneous coronary intervention, Secondary prevention of cardiovascular events in patients with prior myocardial infarction or stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}